Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07032922 · ClinicalTrials.gov registry record

Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome

A clinical trial of Li-Fraumeni Syndrome, sponsored by National Cancer Institute (NCI).

Completed
Registry status
7
Enrollment target
1
Study location

NCT07032922: Completed study of Li-Fraumeni Syndrome, sponsored by National Cancer Institute (NCI).

NCT07032922 is a study of Li-Fraumeni Syndrome that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 7 participants, below the 2,075-participant average among 6 other Li-Fraumeni Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07032922, a study of Li-Fraumeni Syndrome, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
7 participants
Enrollment target
1
Study location

Study Summary

Background: Li-Fraumeni syndrome (LFS) is a genetic disorder that increases the risk of cancer. People who have LFS are 24 times more likely to develop cancer than those who do not. Past research studies have shown that living with high cancer risk can cause distress in young adults with LFS. Mindful self-compassion (MSC) is a therapeutic resource that has helped people with and without cancer cope with distress and other mental health challenges. Researchers at the National Cancer Institute (NCI) want to know if an MSC program can be adapted for young adults with LFS. Objective: Demonstrate and get feedback on an MSC resource for young adults with LFS. Eligibility: Young adults aged 18 to 29 years with LFS who have not participated in an MSC program in the past 6 months and who do not participate in daily meditation for 30 minutes or more. Individuals must be willing to travel to the National Cancer Institute for a one-day demonstration. Design: Participants will answer a short online questionnaire to determine study eligibility, which may include questions about cancer history and mental health. Eligible participants will attend an in-person demonstration of the MSC resource. A small group of other people, such as health care providers, may also attend. Participants will be invited to give their feedback on the MSC resource and discuss how to make it relevant and helpful for young adults with LFS. The demonstration will be held at the NCI campus in Rockville, Maryland. If the demonstration cannot be held in person, it will be conducted virtually. The total time to participate will be about 5.5 hours.

Conditions Studied

Li-Fraumeni Syndrome

Study Locations (1)

Maryland

  • NCI Shady Grove Campus - Rockville

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2025-06-05
Est. Completion 2025-10-31
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT07032922 record still lists

NCT07032922 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 2,075-participant average among 6 other Li-Fraumeni Syndrome trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Li-Fraumeni Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT07032922 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT07032922 about?

NCT07032922 is a clinical study titled "Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome". Background: Li-Fraumeni syndrome (LFS) is a genetic disorder that increases the risk of cancer. People who have LFS are 24 times more likely to develop cancer than those who do not. Past research studies have shown that living with high cancer risk can cause distress in young adults with LFS. Mindf...

What is the current status of trial NCT07032922?

This trial is currently completed. The enrollment target is 7 participants. The study started on 2025-06-05. Estimated completion is 2025-10-31.

What conditions does trial NCT07032922 study?

This clinical trial studies the following conditions: Li-Fraumeni Syndrome.

Who is sponsoring clinical trial NCT07032922?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07032922 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Li-Fraumeni Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT07032922, the US trial registry maintained by the National Library of Medicine. NCT07032922 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.